Shorts

Jason Starr, DO, highlighted a case report wherein a patient received EML4-ALK–targeting treatment and was taken off of hospice, experiencing more than 3 years of survival.

0:51

From Hospice to 3+ Year Survival: Extending Life in EML4-ALK Fusion NEC

6 months ago

Jason Starr, DO

1:05

AI is Changing Breast Cancer Screening

6 months ago

Cancer Network Staff

0:58

Reducing Melanoma Toxicity in Adoptive Cell Therapy

6 months ago

Jose Lutzky, MD

Wendy Stock, MD, spoke with CancerNetwork® about the safety of Orca-T during transplantation for patients with hematologic malignancies such acute lymphoblastic leukemia, acute myeloid leukemia, and myelodysplastic syndrome based on reports from the phase 3 Precision-T trial (NCT04013685).

0:47

How Safe is Orca-T During Transplantation for Hematologic Malignancies?

6 months ago

Wendy Stock, MD

In a conversation with CancerNetwork® at the 3rd Biennial Miami Precision Medicine Conference, Craig H. Moskowitz, MD, discussed the gradually diminishing role that autologous stem cell transplant (ASCT) is playing in the modern lymphoma landscape with the rise of novel treatment modalities.

0:56

Autologous Stem Cell Transplantation is Having a “Slow Death” in Lymphoma

6 months ago

Craig H. Moskowitz, MD

According to Jeff P. Sharman, despite displaying a profound impact on solid tumors, immune checkpoint inhibition has not been explored robustly in lymphomas.

0:43

Is There a Future for Immune Checkpoint Inhibition in Lymphoma?

6 months ago

Jeff P. Sharman, MD

In a discussion with CancerNetwork®, Miranda Gogishvili, MD, spoke about updated efficacy data from the phase 3 EMPOWER-Lung 1 trial (NCT03088540) that she and colleagues presented at the 2026 European Lung Cancer Congress.

0:58

EMPOWER-Lung 1 Shows “Significant Milestone” for Cemiplimab in NSCLC

6 months ago

Miranda Gogishvili, MD

Alexander Z. Wei, MD, discussed strategies clinicians use to reduce the burden of surgery and preserve quality of life among patients with advanced urothelial cancers.

1:17

Highlighting Bladder Preservation Among Vulnerable MIBC Populations

6 months ago

Alexander Z. Wei, MD

0:46

Why mRNA Vaccines Change the Melanoma Game

6 months ago

Jamin C. Morrison, MD

0:45

Comparing HIFU To Surgery and SBRT in Localized Prostate Cancer

6 months ago

Mina Fam, MD

Benjamin Cooper, MD, spoke with CancerNetwork® about the mechanism of JNJ-1900, an investigational nanoparticle radioenhancer, as a treatment for patients with unresectable stage III non–small cell lung cancer as part of the phase 2 CONVERGE trial (NCT06667908).

0:51

Novel Radioenhancer May Help Prevent Disease Recurrence in Stage III NSCLC

6 months ago

Benjamin Cooper, MD

1:00

Why Are Younger Women Getting Diagnosed With Breast Cancer?

6 months ago

Shari B. Goldfarb, MD

In a conversation with CancerNetwork®, Nicole Lamanna, MD, discussed the potential role of minimal residual disease (MRD) as a tool for informing treatment strategies in chronic lymphocytic leukemia (CLL) management.

0:54

Can MRD Influence Therapy Duration in Chronic Lymphocytic Leukemia?

6 months ago

Nicole Lamanna, MD

In a discussion with CancerNetwork®, Nicolas Girard, MD, PhD, highlighted findings from the PALOMA-2 study (NCT05498428) that he and colleagues presented at the 2026 European Lung Cancer Congress.

0:53

PALOMA-2 Shows Benefits of Subcutaneous Amivantamab in EGFR+ NSCLC

6 months ago

Nicolas Girard, MD, PhD

Jeff P. Sharman, MD, identified ways to help expand access to bispecific antibodies among patients with diffuse large B-cell lymphoma.

1:25

Overcoming Institutional Barriers to Bispecific Antibody Access in DLBCL

6 months ago

Jeff P. Sharman, MD

Karie Runcie, MD, provided next steps for improving outcomes in genitourinary cancers, specifically related to kidney cancer.

0:38

Leveraging Neoadjuvant Strategies to Bolster Cure Rates in Kidney Cancer

7 months ago

Karie Danielle Keera Runcie, MD

A recent study that found 10.6% of patients developed a new mental health disorder within 1 year of their cancer diagnosis.

1:16

What New Tools Can Improve Mental Health Screening in Cancer Care?

7 months ago

Julian C. Hong, MD, MS

Karie Runcie, MD, highlighted research she conducted as part of the phase 2 Cyto-KIK trial, a single-arm study assessing cabozantinib and nivolumab in metastatic kidney cancer prior to cytoreductive nephrectomy.

0:49

Cabozantinib Combo Displays Feasibility in Metastatic Kidney Cancer Group

7 months ago

Karie Danielle Keera Runcie, MD

Oxybutynin offered comparable ‘speed-to-relief’ vs comparators among patients experiencing hot flashes while on androgen deprivation therapy for prostate cancer, according to Bradley J. Stish, MD.

0:44

Offering Rapid Relief of Treatment-Emergent Hot Flashes in Prostate Cancer

7 months ago

Bradley J. Stish, MD

$Following the FDA approval of teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients with relapsed/refractory multiple myeloma, María-Victoria Mateos, MD, PhD, spoke with CancerNetwork® about how findings from the phase 3 MajesTEC-3 trial (NCT05083169) support the regimen’s clinical utility.$

0:45

Teclistamab/Daratumumab: An Exciting Combination in R/R Multiple Myeloma

7 months ago

Maria-Victoria Mateos, MD, PhD